You are on page 1of 15

Biotechnological medicines

in development
for prostate cancer
Georgios Lavasidis
Medical student at the
University of Ioannina

Epidemiology
Prostate Cancer (C61): 2008 Estimates
European Age-Standardised Incidence Rates per 100,000 population, Males, EU27 Countries

Epidemiology

sipuleucel-T
› Cellular immunotherapy
› Date of approval (ΕΜΑ):
6/9/2013

Medicines in development

REIC gene therapy
› Clinical trials: Phase Ι/ΙIa
› REIC (Reduced Expression in
Immortalized Cells): tumor
suppressor gene

› Forced gene expression using
adenoviral vector

REIC gene therapy

Adenovirus-mediated REIC/Dkk-3 gene therapy: Development of an autologous cancer
vaccination therapy (Review), Watanabe et al., Oncol Lett. Mar 2014; 7(3): 595–601

REIC gene therapy

Preclinical safety and efficacy of in situ REIC/Dkk-3 gene therapy for prostate
cancer, Kawauchi et al., Acta Med Okayama. 2012;66(1):7-16

Androgen receptor antisense oligonucleotide
(EZN-4176)
› Antisense RNAs: RNAs that bind to complementary mRNAs and
inhibit their translation
› LNA-based oligonucleotide that targets the androgen receptor
(AR)
LNA monomer: The bridge between the
2'-Ο and the 4'-C enhances the stability
of the molecule

› The expression of AR is increased in some prostate cancers
and is related to proliferation and survival of cancer cells

Androgen receptor antisense oligonucleotide
(EZN-4176)
LNA

(AR Gene)

[Clinical trials: Phase I]

Androgen receptor antisense oligonucleotide
(EZN-4176)
(Control)

(Control)

[Preclinical trial]

Reduced expression of the androgen receptor by third generation of antisense
shows antitumor activity in models of prostate cancer, Zhang et al., Mol Cancer
Ther. 2011 Dec;10(12):2309-19

PSA-TRICOM vaccine
› Clinical trials: Phase ΙΙΙ
› Metastatic castration-resistant prostate Ca

Pox-viruses

PSA-TRICOM vaccine

Phase II RCT

Overall survival analysis of a phase II randomized controlled trial of a Poxviralbased PSA-targeted immunotherapy in metastatic castration-resistant prostate
cancer, Kantoff PW et al., J Clin Oncol. 2010 Mar 1;28(7):1099-105

Other possible medicines…
Medicine

Type

Development stage

anti-STEAP1 ADC

mAb-drug conjugate

Clinical trials: Phase Ι

rilotumumab

mAb

Clinical trials: Phase ΙΙ

anti-integrin mAb

mAb

Clinical trials: Phase ΙΙ

ipilimumab

mAb

Clinical trials: Phase ΙΙΙ

nelipepmut-S

peptide vaccine

Clinical trials: Phase Ι/II

BPX-101

dendritic cell vaccine

Clinical trials: Phase Ι/II

GVAX-PCa

immunotherapeutic vaccine

Clinical trials: Phase ΙΙΙ

TeloB-Vax telomerase cancer
vaccine

DNA vaccine

Clinical trials: Phase Ι

AdV-tk + valacyclovir

gene therapy

Clinical trials: Phase ΙΙΙ